Tesla, Inc. (NASDAQ:TSLA – Free Report) – Stock analysts at Zacks Research reduced their Q1 2025 EPS estimates for shares of Tesla in a research report issued on Tuesday, April 15th.

However, active patent challenges require litigation, leading to higher costs. The Zacks Medical – Generic Drugs industry is a small 11-stock group housed within the broader Zacks Medical sector.

Its merger with AK Steel has provided operational synergies and enhanced shareholder value. The Zacks Consensus Estimate for current-year earnings and revenues indicates growth of 20.6% and 5.1% ...

Enter the Zacks Rank. The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, that makes building a ...